Kizub, Darya A. http://orcid.org/0000-0001-7925-2785
Miao, Jieling
Schubert, Mark M.
Paterson, Alexander H. G.
Clemons, Mark
Dees, Elizabeth C.
Ingle, James N.
Falkson, Carla I.
Barlow, William E.
Hortobagyi, Gabriel N.
Gralow, Julie R.
Funding for this research was provided by:
National Cancer Institute (NCI CA180888, CA180819, CA180820, CA180821, CA180868, CA180863)
Susan G. Komen
Breast Cancer Research Foundation
Berlex
Roche
Genentech
Novartis
Article History
Received: 5 June 2020
Accepted: 4 September 2020
First Online: 15 September 2020
Compliance with ethical standards
:
: Dr. Ingle reports grants from U.S. National Cancer Institute, during the conduct of the study. Dr. Falkson reports grants from Seattle Genetics, grants from Pfizer, other from Biotheranostics, other from Agendia, grants from Genentech/Roche, other from ExactSciences/OncotypeDx, outside the submitted work. Dr. Barlow reports grants from the National Cancer Institute, during the conduct of the study. Dr. Hortobagyi reports grants and personal fees from Novartis, outside the submitted work. Dr. Gralow reports other from Roche/Genentech, other from Novartis, other from Radius, other from Astra Zeneca, other from Pfizer, other from Puma, other from Immunomedics, other from Seattle Genetics, other from Sandoz/Hexal AG, outside the submitted work. All other authors declare no conflicts of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. All patients provided written informed consent. The study was approved by the National Cancer Institute Central Institutional Review Board (IRB), as well as by IRBs of participating institutions and monitored by an independent data safety monitoring committee.
: Informed consent was obtained from all individual participants included in the study.
: Does not apply
: Does not apply